CoChat

Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials

Open access
Bhasin, Shalender, Ellenberg, Susan S, Storer, Thomas W, Basaria, Shehzad, Pahor, Marco, Stephens-Shields, Alisa J, Cauley, Jane A, Ensrud, Kristine E, Farrar, John T, Cella, David, Matsumoto, Alvin M, Cunningham, Glenn R, Swerdloff, Ronald S, Wang, Christina, Lewis, Cora E, Molitch, Mark E, Barrett-Connor, Elizabeth, Crandall, Jill P, Hou, Xiaoling, Preston, Peter, Cifelli, Denise, Snyder, Peter J, Gill, Thomas M · 2018 · The Lancet Diabetes & Endocrinology
Cited by 87

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Background We report detailed results of The Physical Function Trial (PFT), one of seven Testosterone Trials (TTrials), which determined testosterone’s effects on mobility, self-reported physical function, falls, and patient global impression-of-change (PGIC) in older men with self-reported mobility limitation and walking speed<1.2 m/sec. We determined if testosterone’s effects on mobility differed according to baseline walking speed, mobility-limitation, or other participant-level factors. Methods The participants were 788 men≥65 years, with total testosterone<275 ng/dL, of which 390 men with mobility limitation and walking speed<1.2 m/sec enrolled in the PFT. Participants were assigned double-blind to 1% testosterone gel or placebo gel daily for 12-months. Primary outcome was Increase in 6-minute walk distance (6MWD) of ≥50 m; secondary outcomes included absolute increase in 6MWD, physical component of Short Form-36 (PF10), and exploratory outcomes PGIC and falls. Findings Intervention groups were similar at baseline. 6MWD improved significantly more in testosterone than in placebo group among all men in TTrials, and separately in men who were not enrolled in the PFT (treatment effect 8.9, 95% CI (2.2,15.6) p=0.01), but not in those who were enrolled in the PFT (treatment effect 4.1, 95% CI (−3.0,11.2) p=0.25). PF10 improved more in testosterone than in placebo group in all men in TTrials (treatment effect 3.1, 95% CI (1.2, 4.9), p=0.002) and separately in both men enrolled and not enrolled in the PFT (treatment effect 2.8, 95% CI (0.41, 5.2), p=0.02; and treatment effect 4.0, 95% CI (1.5, 6.5), p=0.002, respectively). Testosterone-treated men with baseline walking speed ≥1.2 m/sec experienced significantly greater improvements in 6MWD and in PF10 than placebo-treated men. Men reporting mobility limitation showed significantly more improvement in 6MWD and in PF10 than placebo-treated men. Fall frequency was similar in the two groups. Changes in 6MWD were significantly associated with changes in testosterone, free testosterone, DHT, and hemoglobin levels. Interpretation Testosterone consistently improved self-reported walking ability, modestly improved 6MWD in all men participating in the Testosterone Trials, but did not affect falls. Testosterone’s effect on mobility measures in older men with low testosterone were related to baseline gait speed and self-reported mobility limitation, and changes in testosterone and hemoglobin levels. Trial Registration ClinicalTrials.gov number,

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(18)30171-2

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 87

Metadata

Authors
Bhasin, S., Ellenberg, S. S., Storer, T. W., Basaria, S., Pahor, M., Stephens-Shields, A. J., Cauley, J. A., Ensrud, K. E., Farrar, J. T., Cella, D., Matsumoto, A. M., Cunningham, G. R., Swerdloff, R. S., Wang, C., Lewis, C. E., Molitch, M. E., Barrett-Connor, E., Crandall, J. P., Hou, X., Preston, P., Cifelli, D., Snyder, P. J., & Gill, T. M.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2018-11
Volume
6
Issue
11
Pages
879-890
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2898216717
Cited by
87
References
21
FWCI
6.14
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. https://app.cochat.ai/papers/10.1016/s2213-8587(18)30171-2
The paper
Bhasin, S., Ellenberg, S. S., Storer, T. W., Basaria, S., Pahor, M., Stephens-Shields, A. J., Cauley, J. A., Ensrud, K. E., Farrar, J. T., Cella, D., Matsumoto, A. M., Cunningham, G. R., Swerdloff, R. S., Wang, C., Lewis, C. E., Molitch, M. E., Barrett-Connor, E., Crandall, J. P., Hou, X., . . . Gill, T. M. (2018). Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(18)30171-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.